Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 6, 2026Blood

Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCL

View Full Paper
Ask AI
Bookmark
Share

Authors

JAJeremy AbramsonTSTanya SiddiqiLGLeo I. Gordon

Discussion

Loading...

Member takes

Overview

Randomized trial reports improved survival outcomes in patients with R/R LBCL, suggesting potential benefits of liso-cel treatment.

Key Points

  • To evaluate the 5-year survival outcomes of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.
  • Analyzed data from TRANSCEND NHL 001 and long-term follow-up study.
  • Involved 345 patients who underwent leukapheresis, with 270 receiving liso-cel and 257 being efficacy evaluable.
  • Calculated overall survival and disease-specific survival rates at five years.
  • Median overall survival was 27.5 months (95% CI, 16.2-47.3) with a 5-year OS rate of 38% (95% CI, 32-45).
  • Median disease-specific survival was 67.8 months (95% CI, 23.5-NR) with a 5-year DSS rate of 52% (95% CI, 45-59).
  • Among patients who enrolled in the long-term follow-up, estimated 5-year OS rate was 78% (95% CI, 67-86) and DSS rate was 92% (95% CI, 84-97).

Cite This Study

Abramson et al. (2026) studied this question.

synapsesocial.com/papers/6a23bb7971a5da9775e76e82https://doi.org/10.1182/blood.2025032270
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL): First results from CIBMTR.2026
  2. 2Lisocabtagene maraleucel (liso-cel) in patients (pt) with R/R mantle cell lymphoma (MCL): Subgroup analyses by number of prior systemic lines of therapy (LOT) and by response to prior Bruton tyrosine kinase inhibitor (BTKi) from the TRANSCEND NHL 001 MCL cohort (TRANSCEND-MCL).2024 · 3 citations
  3. 3Outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with relapsed or refractory (R/R) mantle cell lymphoma (MCL): First real-world data from the CIBMTR.2026
  4. 4Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study2024 · 143 citations
  5. 5Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL2025 · 2 citations